ConductScience.org, home

Comparison · NCT03252249-59e31a29

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding. Trial comparisons, record NCT03252249-59e31a29. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03252249-59e31a29

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04120.03410.0496wilson
Risk in group 20.05030.04240.0595wilson
Risk difference, group 1 minus group 2-0.00911-0.02070.00245newcombe hybrid score
Risk ratio, group 1 over group 20.8190.6361.05log
Odds ratio, group 1 over group 20.8110.6221.06log
Number needed to treat, for one fewer participant with the outcome on 3 Months Dual Anti-platelet Therapy than on 12 Months Dual Anti-platelet Therapy110from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 13 Months Dual Anti-platelet Therapy3 months dual anti-platelet therapy.~3 months dual anti-platelet therapy: Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.1042,526OG000
Group 212 Months Dual Anti-platelet Therapy12 months dual anti-platelet therapy.~12 months dual anti-platelet therapy: Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.1272,526OG001

Outcome

Type
SECONDARY
Title
Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding
Description
Occurrence of event
Time frame
Date of MI to 15 months
Population
The intention to treat (ITT) principle. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention.

Source ClinicalTrials.gov

Trial

Title
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
NCT number
NCT03252249
Phases
PHASE4
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Interventions
3 months dual anti-platelet therapy, 12 months dual anti-platelet therapy
Lead sponsor
University of Edinburgh
Results first posted
2026-01-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03252249-59e31a29